A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: AB801
DRUG: Docetaxel

Sponsor

Arcus Biosciences, Inc.